Moleculin Biotech Inc (MBRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.02M
Last updated: Nov 17, 2026 at 10:59 AM ET
Moleculin Biotech Inc (MBRX) Competitors
The companies most similar to Moleculin Biotech are Marker Therapeutics (MRKR), GT Biopharma (GTBP) and Tempest Therapeutics (TPST). By market cap, Moleculin Biotech ranks 9th of the 13 companies on this page; Marker Therapeutics (MRKR) is the largest at $14.51M.
Peer Comparison
MBRX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Moleculin Biotech (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $9.90M | N/A | 16.4x | 0.0% | -72.3% | -15.9% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Biovie Inc (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| In8bio Inc (INAB) | $8.86M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Quantum BioPharma Ltd. (QNTM) | $10.35M | N/A | N/A | 0.0% | -150.1% | 0.0% | 0.00% |
| Vyome Holdings, Inc. (HIND) | $11.09M | N/A | N/A | 0.0% | N/A | 67.5% | 0.00% |
| Chemomab Therapeutics Ltd DRC (CMMB) | $12.31M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Longeveron LLC (LGVN) | $8.40M | N/A | 5.9x | 0.0% | N/A | -9.2% | 0.00% |
| Aprea Therapeutics Inc (APRE) | $5.91M | N/A | N/A | 0.0% | N/A | -98.4% | 0.00% |
| Peer median | $9.38M | N/A | 15.5x | 0.0% | -111.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Moleculin Biotech, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human... | |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Biovie Inc (BIVI) | BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. | BIVI competitors |
| In8bio Inc (INAB) | IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers... | INAB competitors |
| Quantum BioPharma Ltd. (QNTM) | Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases. | QNTM competitors |
| Vyome Holdings, Inc. (HIND) | Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States... | HIND competitors |
| Chemomab Therapeutics Ltd DRC (CMMB) | Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. | CMMB competitors |
| Longeveron LLC (LGVN) | Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions. | LGVN competitors |
| Aprea Therapeutics Inc (APRE) | Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor... | APRE competitors |
Frequently Asked Questions About MBRX
Who are Moleculin Biotech's main competitors?
The companies most similar to Moleculin Biotech include Marker Therapeutics (MRKR), GT Biopharma (GTBP), Tempest Therapeutics (TPST), CytoMed Therapeutics Limited Ordinary Shares (GDTC) and Theriva Biologics (TOVX), listed from the closest match.
Who is Moleculin Biotech's biggest competitor?
Marker Therapeutics (MRKR) is both the largest of the similar companies at $14.51M and the closest match by business profile, size, sector and industry.
How does MBRX stock compare with its competitors?
MBRX's net margin is 0.0% against a peer median of 0.0%.
Which of Moleculin Biotech's competitors pays a higher dividend?
Moleculin Biotech pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Moleculin Biotech bigger than its competitors?
No. Moleculin Biotech is 9th by market cap among the 13 companies on this page; the largest is Marker Therapeutics (MRKR) at $14.51M.
MBRX pages: Overview, Earnings, Forecast, Financials, Competitors